SCHEMBL6461530

SCHEMBL6461530

CC(=O)OCCC(COC(C)=O)c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 9/20 0.40
ESR2 Q92731 6/20 0.40
TDP1 Q9NUW8 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP2D6 P10635 3/20 0.37
ALDH1A1 P00352 2/20 0.37
CHRM1 P11229 2/20 0.37
SLC6A2 P23975 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 2/20 0.37
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDR P35968 1/20 0.37
LMNA P02545 2/20 0.35
ALOX15 P16050 2/20 0.35
CYP2C19 P33261 2/20 0.35
PGR P06401 1/20 0.35
CHRM2 P08172 1/20 0.35
CYP3A4 P08684 1/20 0.35
ADORA3 P0DMS8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830770 0.81 ALDH1A1 (0.43) ESR1ESR2TDP1CYP1A2CYP2D6
SCHEMBL10896453 0.79 ESR1 (0.40) ESR1ESR2TDP1CYP1A2CYP2D6
SCHEMBL416523 0.78 ALDH1A1 (0.46) ESR1ESR2TDP1CYP1A2CYP2D6
SCHEMBL6461779 0.77 CTNNB1 (0.41) TDP1ALDH1A1SMN1; SMN2ARPRKCA
SCHEMBL10896449 0.76 ESR1 (0.36) ESR1ESR2TDP1CYP1A2CYP2D6
SCHEMBL931297 0.75 ESR1 (0.42) ESR1ESR2TDP1CYP1A2CYP2D6
SCHEMBL2602795 0.73 CYP1A2 (0.47) CYP1A2CYP2D6ALDH1A1SMN1; SMN2TSHR
SCHEMBL1864554 0.73 CYP1A2 (0.49) TDP1CYP1A2CYP2D6ALDH1A1SMN1; SMN2
SCHEMBL9771995 0.72 CYP1A2 (0.67) CYP1A2CYP2D6ALDH1A1CHRM1SMN1; SMN2
SCHEMBL11108674 0.71 ESR1 (0.42) ESR1ESR2TDP1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050203094-A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors AXYS PHARMACEUTICALS, INC. 2005-09-15 US disclosed
EP-1474400-A1 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-11-10 EP disclosed
WO-2003068756-A1 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)]-6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203094-A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors F7, HABP2, F13B ESR1 2842/4885ESR2 1100/4885TDP1 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.